Loading…
Loading…
ELOX (Eloxx Pharmaceuticals, Inc.) is a recent IPO.
It began trading on June 9, 2026, giving it a few months of public history. Many charts and metrics below are sparse or empty until more price, financial, and analyst history accumulates — the affected sections are flagged individually so you can tell limited history from missing data.
ELOX does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ELOX and 80,000+ other tickers.
See exactly how ELOX's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ELOX and 80,000+ other tickers.
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature stop codons. The company's most advanced investigational compound, ELX-02, is currently progressing through Phase 2 clinical trials. This candidate is being evaluated for its potential to treat patients with cystic fibrosis and nephropathic cystinosis who possess diagnosed nonsense mutations. In addition to its lead program, Eloxx is actively pursuing…
Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026 European Commission granted orphan designation for exaluren in ADPKD Cash and cash equivalents of $62.0 million as of June 30, 2026, expected to fund operations through data readouts for both Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD) ARLINGTON, Mass., Aug. 12, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today reported financial results for the second quarter ended June 30, 2026 and provided a business update.
ARLINGTON, Mass., June 8, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) ("Eloxx" and the "Company"), a clinical-stage biopharmaceutical company developing novel, small molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations to enable the production of full-length proteins, today announced the pricing of a public offering of 2,975,000 shares of common stock at a public offering price of $11.00 per share and, in lieu of shares of common stock, pre-funded warrants to purchase up to 3,025,000 shares of common stock at a public offering price of $10.99 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.01 per share exercise price of each pre-funded warrant.
Eloxx Pharmaceuticals (NASDAQ: ELOX - Get Free Report) and Prime Medicine (NYSE: PRME - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation. Profitability This table compares Eloxx Pharmaceuticals and Prime
Risk and Volatility Eloxx Pharmaceuticals has a beta of -1720.35, suggesting that its share price is 172,135% less volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500. Profitability This table compares Eloxx Pharmaceuticals and Finch Therapeutics Group's
Profitability This table compares Finch Therapeutics Group and Eloxx Pharmaceuticals' net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Finch Therapeutics Group N/A -69.14% -26.92% Eloxx Pharmaceuticals N/A N/A N/A Earnings and Valuation This table compares Finch Therapeutics Group and Eloxx Pharmaceuticals"s revenue, earnings per share and